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Abstract We have recently shown that calmodulin (CaM)
regulates the trafficking of epidermal growth factor receptor
(EGFR) as well as the mitogen-activated protein kinase (MAPK)
signalling pathway. However, the overall regulation of the
MAPK pathway is achieved through a complex interplay of
other several upstream effectors including G-proteins, EGF,
EGFR, protein kinase C (PKC), phosphatidylinositol-3-kinase
and CaM. In order to understand the role of CaM in the PKC-
mediated transactivation of EGFR we have analysed the effect of
a CaM antagonist, N-(4-aminobutyl)-5-chloro-2-naphthalenesul-
fonamide, on the 12-O-tetradecanoylphorbol-13-acetate-
mediated activation of EGFR and the subsequent MAPK
activation. The results show that CaM interferes with MAPK
activation and the transactivation of EGFR mediated by
PKC. ß 2002 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Calmodulin (CaM) is the most abundant calcium-binding
protein in non-muscle cells that function as second messenger
in a variety of cellular processes including the organisation of
cytoskeleton, cell proliferation [1^3] and membrane tra⁄cking
[4,5]. The recognition by Ca2/CaM of a short polypeptide
segment in target proteins (CaM-binding proteins, CaMBPs)
induces conformational changes in both CaM and the target,
enabling the target protein to become functionally active [6].
The epidermal growth factor receptor (EGFR) is a CaMBP
[7].
Using a CaM antagonist, N-(4-aminobutyl)-5-chloro-2-
naphthalenesulfonamide (W-13), we have recently demon-
strated a speci¢c stimulation of tyrosine-phosphorylation of
the EGFR despite the decrease in mitogen-activated protein
kinase (MAPK) activity caused by interference on Raf-1 ac-
tivity [5,8]. In addition, the W-13-mediated EGFR-phosphor-
ylation was shown to be blocked by a metalloproteinase in-
hibitor (batimastat, BB94), indicating the possible
involvement of shedding in this process [5]. The involvement
of CaM in the regulation the MAPK pathway has been de-
scribed at various levels : (1) it binds to EGFR and negatively
regulates its tyrosine kinase activity [9]; (2) it also binds to
Ras (K-Ras), modulating its downstream signalling [10]; (3)
CaM through the CaM kinase II phosphorylates EGFR and
thus inhibits its tyrosine kinase activity [11]. Nevertheless, the
overall regulation of the MAPK signalling pathway is much
more complex with a range of intermediate molecules in-
volved (e.g. G-proteins, protein kinase C (PKC), phosphati-
dylinositol-3-kinase, EGFR/EGF or by EGFR transactiva-
tion) [12].
The interplay of CaM and PKC in the transactivation of
EGFR remains unclear; PKC binds and phosphorylates ki-
nases, such as EGFR, providing a mechanism for cross-regu-
lating the phosphorylation state and its catalytic activity [13];
binding of CaM inhibits the PKC-mediated phosphorylation
of EGFR [14,15]. Apparently, the PKC-induced phosphory-
lation of the EGFR at threonine-654 (Thr654), is su⁄cient to
direct incoming receptors to the recycling endosomes, whereas
phosphorylation at tyrosine residues directs the receptor to
the MVB/late endosomal compartment [14], in agreement
with the close relationship between endocytosis, tra⁄cking,
sorting and signalling events. Furthermore, CaM kinase II
or extracellular factors (released by shedding) might regulate
the transactivation of EGFR by PKC activation or by
changes in the content (or re-distribution) of CaM [16,17].
The augmented transactivation of EGFR, through PKC, in-
creases MAPK activation [16].
In the present study we show that in COS-1 cells CaM
interferes with the transactivation of EGFR mediated by
PKC and, consequently, inhibition of PKC partially blocks
the CaM-dependent EGFR transactivation. CaM is also in-
volved in the PKC-mediated activation of Ras.
2. Materials and methods
2.1. Reagents and antibodies
W-13, W-12 and tyrphostin (AG1478) were from Sigma (Madrid,
Spain). A monoclonal antibody to the extracellular domain of the
EGFR (Ab225) was obtained from the American Type Culture Col-
lection (Rockville, MD, USA); the rabbit polyclonal antibodies
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against phosphorylated MAPK or phosphorylated MEK were from
Cell Signaling, NEBiolabs (Beverly, MA, USA), the monoclonal anti-
(pan)-Ras was from Oncogene Sciences (Cambridge, MA, USA);
horseradish peroxidase (HRP)-protein A was from Zymed (San Fran-
cisco, CA, USA). Peroxidase-labeled antibodies and sodium dodecyl
sulphate^polyacrylamide gel electrophoresis (SDS^PAGE) molecular
weight markers were from Bio-Rad. BB94 was from British Biotech
(UK). Bisindolylmaleimide (BIM) and 12-O-tetradecanoylphorbol-13-
acetate (TPA) were from Calbiochem (Merck Eurolab, Darmstadt,
Germany); neutralising antibodies to amphiregulin (AR) (anti-AR,
anti-heparin-binding EGF-like growth factor (anti-HB-EGF) and
anti-transforming growth factor-K (anti-TGFK) were from RpD Sys-
tems Europe (Abingdon, UK). Finally, the anti-phosphotyrosine-
RC20 HRP-conjugated was from Transduction Laboratories (Becton
Dickinson, San Diego, CA, USA) and the rabbit polyclonal anti-
EGFR antibody (Ab1005) from Santa Cruz (Santa Cruz, CA, USA).
2.2. Cell culture
Green monkey kidney cells (COS-1) were grown in Dulbecco’s
modi¢ed Eagle’s medium (DMEM) containing 10% foetal calf serum
(FCS), antibiotics and glutamine. DMEM and FCS were purchased
from Biological Industries (Beit Haemek, Israel). Cells were grown to
about 90% con£uence, and starved overnight in those experiments
where lysates were used.
2.3. Cellular extracts
After the various treatments (as indicated in ¢gure legends), COS-1
cells (in 35 mm dishes) were lysed in a bu¡er containing 2% SDS, 67
mM Tris^HCl pH6.8 and 10 mM EDTA, and sonicated twice for 10 s
on ice. Equal amounts of protein were electrophoresed and immuno-
blotted.
2.4. Measurement of Ras activation
The capacity of Ras-GTP to bind to the Ras-binding domain
(RBD) of Raf-1 was measured to analyse the amount of active Ras
[18]. Cells (2U106) were lysed in the culture dish (100 mm) with lysis
bu¡er (20 mM Tris^HCl, pH 7.5, 2 mM EDTA, 100 mM NaCl, 5 mM
MgCl2, 1% (v/v) Triton X-100, 5 mM NaF, 10% (v/v) glycerol, 0.5%
(v/v) 2-mercaptoethanol) plus protease and phosphatase inhibitors.
Cleared lysate (10 000Ug) was assayed for protein concentration
according to the method of Bradford [19] and protein-equalised super-
natants were incubated for 2 h at 4‡C with glutathione Sepharose-4B
beads pre-coupled to GST-RBD. Beads were washed four times in the
lysis bu¡er. Bound proteins were solubilised by the addition of 30 Wl
of Laemmli [20] loading bu¡er and run on 12.5% SDS^PAGE gels.
The amount of Ras in the bound fraction was analysed by Western
blotting using anti-(pan)-Ras (Ab-3, OP-40, Oncogene Sciences)
monoclonal antibody.
3. Results
Recent evidence showed the transactivation of EGFR by
phorbol ester (TPA)-dependent activation of PKC [16]. How-
ever, since CaM binds and regulates the EGFR signalling we
studied the involvement of CaM, as an upstream e¡ector, in
the EGFR transactivation and in the overall regulation of the
MAPK signalling pathway.
3.1. CaM modulates the PKC transactivation of EGFR
In COS-1 cells, TPA (100 nM), increased the EGFR-tyro-
sine phosphorylation. This e¡ect was blocked when cells were
pre-incubated with Ab225, which prevented the EGF binding
site and therefore the extracellular activation of EGFR (Fig.
1A) or after pre-incubation with AG1478 (10 WM), a speci¢c
inhibitor of the EGFR tyrosine kinase activity (Fig. 1A).
To examine whether the e¡ect of W-13 was dependent on
PKC activity, COS-1 cells were treated with BIM, a PKC
inhibitor, before W-13 treatment. Equal amounts of lysates
were electrophoresed and the levels of phosphotyrosine
EGFR were analysed by Western blot, using the antibody
R-C20 HRP-conjugated. Fig. 1B shows that BIM reduces
(60%, n = 3) the e¡ect of W-13 on EGFR tyrosine phosphor-
ylation. This indicates that CaM modulates the transactiva-
tion of EGFR by PKC.
Our previous studies showed that W-13-mediated EGFR
transactivation requires metalloproteinase activity and subse-
quent release of growth factors that bind and stimulate the
EGFR through an extracellular mechanism [5]. The shedding
of di¡erent ligands can be promoted by activation of PKC
[21,22] or through antagonists of CaM [23]. A battery of
neutralising antibodies against some of the most common
growth factors was tested. HB-EGF inhibited the W-13-stimu-
lated phosphorylation of EGFR (Fig. 1C); in fact, shedding
of HB-EGF was described after PKC activation [24].
These results indicate that transactivation of EGFR, possi-
bly through the release of HB-EGF, by W-13 could be medi-
ated by PKC.
Fig. 1. TPA and W-13 e¡ects on tyrosine phosphorylation of
EGFR. A: COS-1 cells were pre-incubated with Ab225 (10 Wg/ml)
or AG1478 (5 WM) for 15 min, and then treated with TPA (100
nM) for 15 min at 37‡C. Equal amounts of protein were electropho-
resed and analysed by Western blotting with anti-phosphotyrosine
RC-20 antibody HRP-conjugated or with Ab1005, for the EGFR.
PKC-mediated EGFR tyrosine phosphorylation is inhibited in the
presence of Ab225 or AG1478. B: Treatment with the PKC inhibi-
tor BIM (6 WM) together with W-13 (10 Wg/ml) for 30 min. A di-
minution of W-13-mediated EGFR phosphorylation can be ob-
served when BIM was present. C: The e¡ect of pre-incubation (30
min) of di¡erent neutralising antibodies: anti-AR (50 Wg/ml), anti-
HB-EGF (10 Wg/ml) or anti-TGFK (10 Wg/ml) on W-13 tyrosine
phosphorylation of EGFR was analysed by Western blotting. Only
the anti-HB-EGF has an inhibitory e¡ect on the W-13-stimulated
phosphorylation of EGFR.
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3.2. AG1478 and the metalloproteinase inhibitor BB94 partially
block MEK activation by TPA
To ascertain the involvement of CaM in the PKC response
we studied the e¡ect of W-13 on EGFR tyrosine phosphory-
lation by TPA and whether the increase in tyrosine phosphor-
ylation of the EGFR activates the MAPK pathway. The levels
of P-MEK were analysed in lysates of COS cells treated with
TPA (100 nM) and/or W-13 (10 Wg/ml) in the absence or
presence of AG1478 or the metalloproteinase inhibitor BB94
(6 WM). Fig. 2A shows that W-13 potentiated (synergistic
e¡ect) the TPA e¡ect on EGFR tyrosine phosphorylation. It
also shows the activation of MEK by TPA, and that W-13
diminished P-MEK. W-13 acts upstream of MEK inhibiting
Raf-1 activity [5] and therefore no synergistic e¡ect of TPA in
MEK activation occurred. Interestingly, AG1478 partially re-
duces the TPA activation of MEK and the subsequent MAPK
activation (Fig. 2A).
The same can be observed when the metalloproteinase in-
hibitor, BB94, was used. Fig. 2B shows that in cells treated
with TPA and BB94, P-MEK was not completely inhibited.
This result suggests that in our system phorbol esters could
activate the MAPK pathway at least by two ways, one depen-
dent on EGFR transactivation and the second independent of
the shedding.
3.3. W-13 facilitates Ras activation by PKC
To study whether CaM modulates the activation of the in-
dependent EGFR transactivation of the MAPK cascade by
PKC, and to bypass the inhibitory e¡ect of W-13 on the Raf-1
activity, pull-down experiments were performed to analyse the
amount of active Ras (Ras-GTP), using GST-RBD recombi-
nant protein. Fig. 3 shows that the metalloproteinase inhibitor
BB94 dramatically reduced the levels of Ras-GTP raised by
TPA and this inhibition was restored in the presence of W-13.
Thus, it can be concluded that CaM is crucial for the PKC-
mediated MAPK activation in the EGFR-independent Ras
pathway.
4. Discussion
The results of the present study show, in agreement with
Chen et al. [16], that PKC is responsible for the stimulation of
MAPK through the transactivation of EGFR; in addition, we
now demonstrate that this e¡ect can be magni¢ed in the pres-
ence of the CaM antagonist W-13, and that CaM exerts an
additional e¡ect in the control of the MAPK signalling path-
way.
The mechanisms of the PKC-induced EGFR transactiva-
tion are complex and involve regulators at di¡erent levels.
CaM, an intracellular calcium regulatory protein, is directly
involved in the proteolytic cleavage of the ectodomain of cer-
tain membrane-bound proteins [23]. However, multiple signal
transduction pathways can regulate the release of EGFR li-
gands. Here, in this study we show a synergistic e¡ect of TPA
(PKC) and W-13 (inhibition of CaM) in the EGFR transacti-
vation and the subsequent activation of the MAPK signalling
pathway.
It has been reported that PKC activation stimulates TGFK,
HB-EGF and AR release [25,21]. Experimental evidence
points to a possible common mechanism for PKC-regulated
release of other cell surface proteins, involving the interaction
of metalloproteinases with PKC, as shown for MD9/ADAM9
Fig. 2. AG1478 and BB94 partially block MAPK activation by
PKC. COS-1 cells were pre-incubated with AG1478 (5 WM) (A) or
BB94 (6 WM) (B) for 5 or 15 min at 37‡C, respectively. Then, cells
were treated with TPA and/or W-13 (15 min). A: Lysates of equal
amounts of protein were electrophoresed and phosphotyrosine of
EGF-R, MEK activation (P-MEK) or MAPK (P-Erks) were de-
tected by Western blotting with anti-phosphotyrosine RC-20 anti-
body HRP-conjugated, polyclonal antibody to P-MEK or to
P-Erks, respectively. In the absence of AG1478 a synergistic e¡ect
can be observed of W-13 and TPA on the tyrosine phosphorylation
of EGFR not found on P-MEK or P-Erk. B: E¡ect of the metallo-
proteinase inhibitor, BB94, on the P-MEK activated by TPA or
TPA+W-13. In both panels (A and B) it can be seen that AG1478
or BB94 treatments do not completely block MEK activation.
Fig. 3. BB94 does not inhibit Ras activation by TPA in presence of
W-13. COS-1 cells grown in 100 mm dishes were incubated with
TPA (100 nM) and/or W-13 (10 Wg/ml) for 15 min at 37‡C and Ras
activation (Ras-GTP) was assessed by GST-RBD pull-down, as de-
scribed in Section 2. Ras-GTP levels were assessed in the presence
or absence of the metalloproteinase inhibitor BB94. When metallo-
proteinases were inhibited (+BB94) it can be observed that incuba-
tion of TPA+W-13 restored the amount of activated Ras.
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and PKCN in the PMA-induced shedding of HB-EGF in
Vero-H cells [24]. However, calcium in£ux and tyrosine phos-
phatase activity also regulate the release of EGFR ligands
independent of PKC activity [26,27].
When cells were incubated with metalloproteinase inhibi-
tors such as BB94 they became insensitive to the stimulation
of EGFR by W-13 [5]. Since recent studies showed that CaM
interferes with the shedding of di¡erent molecules [28] we used
W-13 to ¢nd out whether activation of the shedding was de-
pendent on or independent of PKC. In the present study we
showed that HB-EGF seems to be involved in the transacti-
vation of EGFR mediated by W-13, since it was shown that
incubation with the anti-HB-EGF results in inhibition of the
tyrosine phosphorylation of EGFR by W-13.
Regarding the cross-communication between PKC and
CaM ^ in the presence of metalloproteinase inhibitors ^ for
the modulation of Ras-GTP levels and the subsequent MAPK
activation, it is conceivable that the direct interaction between
Ras and CaM [10] may be responsible for the modulation of
PKC on the Ras-GTP levels, by a still unknown mechanism.
CaM is the key molecule, which may control the MAPK
signalling pathway at di¡erent levels ; the role of calcium in
the activation of CaM is controversial and may di¡er for
di¡erent CaM targets. For example, the requirement for cal-
cium is not absolute for CaM binding to L-selectin in vitro
[28]. Therefore, location vs. redistribution of CaM by calcium-
dependent or -independent mechanisms as well as the di¡er-
ential a⁄nity for CaMBPs, will be decisive for the overall
cellular physiology.
Finally, there is the question of where these events take
place. Since most signal transduction processes utilise co-lo-
calisation of sequentially acting signalling proteins for the
selective activation of downstream functions, it is remarkable
that in cells treated with W-13 there was an inhibition of the
tra⁄cking events leading to the recycling or the degradative
pathways [5] ; this inhibition of the budding (exit) from aber-
rant large early endosomal compartment could be responsible
for the regulation of MAPK signal transduction. Compart-
mentalisation (recruitment) of the signal transduction machin-
ery in the endocytic compartment may facilitate the interac-
tion between di¡erent ‘modules’ involved in the regulation of
key events that control the activation of MAPK [29^35].
A simplify model which envisage possible intersections be-
tween EGFR, PKC and the novel involvement of CaM in the
control of the MAPK signalling pathway is shown in Fig. 4.
Our data are compatible with a possible general mechanism
by which CaM and PKC have an antagonistic e¡ect. For
instance, it has been reported that phosphorylation of recep-
tors such as the EGFR [9] or the metabotropic glutamate
receptor [36], by PKC prevents its interaction with CaM,
and conversely CaM binding inhibits phosphorylation. Other
CaMBPs such as MARCKS or adducin seem to be equally
regulated.
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